Piyasa kapalı· · ILA · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
NMPA approval supported by a 200-subject, randomized, controlled study in China demonstrating statistically significant improvement in mid-to-lower facial wrinkles and a favorable safety profile China represents a growing medical aesthetic market, with the market for non-invasive/minimally invasive procedures valued at RMB 146.0 billion (approximately US$20.6 billion) in 20231 SAN CLEMENTE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthe
SAN CLEMENTE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference on September 8-10, 2026. About Sofwave MedicalSofwave Medical Ltd. (TASE: SOFW) is a global
A prospective randomized controlled trial of an aesthetic EMS platform to assess objective functional performance reports improvements across four standardized testsSAN CLEMENTE, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthetics company advancing non-invasive technologies for skin and body, today announced the publication of data from a new randomized controlled clinical study of the Company’s proprietary PlyoPulse™ technology, titled “
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.